Overview

Lurasidone Pediatric Autism Study

Status:
Completed
Trial end date:
2014-11-01
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of 2 fixed doses of lurasidone (20 mg/day and 60 mg/day) for 6 weeks compared with placebo in pediatric and adolescent subjects with irritability associated with autistic disorder who reside in the community setting.
Phase:
Phase 3
Details
Lead Sponsor:
Sunovion
Treatments:
Lurasidone Hydrochloride